Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

NEW YORK – Arrowhead Pharmaceuticals on Monday said it has treated the first patients with ARO-ALK7, an RNAi therapeutic that the company is developing for obesity, within a first-in-human Phase I/IIa ...

Sanofi will gain Blueprint's Ayvakit, a treatment for systemic mastocytosis and gastrointestinal stromal tumors, among other therapies in its pipeline.

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Due to financial, logistical, and regulatory barriers, only two in 10 patients eligible for CAR T-cell therapy in the US ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

The biotech startup, a spinout of the University of Colorado Anschutz Medical Campus, launched this year with $15 million in ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.